What if you could heal like Wolverine?
That's the fantasy fueling one of the hottest trends in the rapidly expanding world of injectable peptides—the so-called "Wolverine stack," a combination of the clinically named BPC-157 and TB-500 injected by biohackers, wellness influencers, athletes, and others eager to accelerate recovery from injuries.
The name captures the appeal. A comic-book superhero from the Marvel universe, Wolverine can heal from major injuries with supernatural speed. Why, then, wait weeks or months for a tendon to feel better when a peptide injection might help you bounce back like a superhero?
And the promises extend well beyond injuries. Spas, wellness clinics, telehealth companies, and online vendors lure people in with claims that injectable peptides can rejuvenate skin, repair damaged tissue, speed up recovery from surgeries, tamp down inflammation, bolster sleep, and boost muscle mass, libido, and vitality. Want to look 10 years younger? Try this peptide. Need that torn hamstring healed before your next Ironman? This one's for you.
Behind the enthusiasm, however, critical questions linger: Do the drugs actually work? Are they safe?
Christopher Robinson, a physician-scientist at the Johns Hopkins University School of Medicine who specializes in chronic pain and regenerative medicine, understands the appeal and is seeking federal funding to study peptides in his lab. But he and other doctors worry about the many unknowns surrounding these unregulated substances as consumer demand rises.
"People need to understand that there's a huge difference between peptides that have been rigorously studied and approved as medications, such as insulin and GLP-1 weight-loss drugs, and these newer compounds," Robinson says. "These other peptides haven't been adequately studied in humans and aren't approved by the Food and Drug Administration. Anyone who uses them needs to understand the risks."
In many cases, Robinson stresses, people are injecting themselves with compounds that have only been studied in mice and rats, not humans. "That's alarming," he adds.
Yet as scientists work to answer basic questions about safety and effectiveness, a booming commercial industry and proposed changes to the FDA's policies could bring peptides into the mainstream.
From messenger to medicine
Part of what makes peptides enticing is that our bodies already make and rely on them.
Short chains of amino acids, peptides act as chemical messengers, helping cells communicate and regulating everything from immune function and tissue repair to pain signaling, digestion, and metabolism. Because peptides bind to specific receptors on cells, they operate like tiny keys fitting into locks. For instance, when a peptide binds to its receptor, it tells a cell to do something—block pain, relieve stress, slow digestion, or stimulate collagen, the protein that firms up skin and strengthens bones, tendons, ligaments, and cartilage.
Scientists can build synthetic peptides in labs, stringing together amino acids in precise sequences to recreate those in the body or tweaking them to achieve a particular goal. And manufacturers use those lab-made versions in a range of products, including lifesaving medicines like insulin, used since 1923 to treat diabetes; GLP-1 weight-loss and diabetes management drugs; and Pitocin, given to women in labor to progress and ease pain during childbirth.
But lab-made peptides also make up a broader, and much less regulated, wellness marketplace. Manufacturers add them to skin-care products and dietary supplements, while spas, telehealth companies, and online vendors offer injectable versions that consumers can administer with syringes at home or opt for practitioners to deliver in clinics.
Vials come with individual peptides or combinations of peptides known as a "stack." Someone wanting more energy or faster metabolism, for instance, might turn to the peptide MOTS-c. Or for an all-purpose upgrade to the body, a stack of peptides known as the "Kitchen Sink" could be suggested. It combines the Wolverine peptides with others such as CJC-1295 and ipamorelin, purportedly packing a powerful punch into a single routine shot to do it all: build muscle, eliminate fat, speed recovery, boost energy, and turn back the clock on aging.
The names and uses vary, but Robinson says they share a crucial limitation: The evidence in humans is thin.
"All of these drugs are purely experimental," Robinson says. "Vials often come with 'for research purposes only' labels, meaning they are intended for research only, not regular clinical use."
People inject them anyway.
A growing gray market
Much of that trade exists in a murky space beyond the conventional FDA-approved drug system. Most often, these peptides come from overseas suppliers—China is the biggest producer—but consumers can sometimes get them from U.S. pharmacies operating under different rules for compounded medicines.
Data doesn't exist to pinpoint just how large the gray market for injectable peptides has become. But market analyses depict enormous growth, with much of the trade conducting financial transactions in cryptocurrencies like Bitcoin and stablecoin, which are untraceable and commonly used in illicit deals. Chainalysis, a cryptocurrency tracking firm whose work is often covered by major news outlets, found that money flowing to gray-market peptide vendors is on track to surpass $100 million this year, up from $4 million in 2024. Until recently, "the gray-market peptide ecosystem was a niche, underground space, averaging just $200,000 in monthly inflow volume," Chainalysis reports. The boom comes as some Chinese chemical manufacturers pivot from supplying fentanyl and ingredients to make amphetamines to transnational drug cartels—and tap into the unregulated peptides market, the firm says.
Meanwhile, a steady stream of celebrity endorsements and online testimonials is accelerating the growth of peptide compounds. In podcasts and across social media, actor Josh Duhamel and the popular wellness guru and podcast host Joe Rogan praise the Wolverine stack's prowess in injury recovery, while other celebrities and wellness influencers promote peptide injections as core to their skincare regimens, energy, and longevity. Across Reddit, Facebook groups, and other online forums, ordinary users swap stories and share tips about what they inject, how much they take, where to buy it, and whether it worked.
Another powerful advocate is Robert F. Kennedy Jr., secretary of the U.S. Department of Health and Human Services, which oversees the FDA and other federal health agencies. This past February on the Joe Rogan Experience podcast, Kennedy appeared as a guest and said of peptides: "I'm a big fan." He told audiences he'd used them with good results for injuries and predicted that the FDA would take steps to make previously restricted compounds more accessible.
Five months later, the FDA's Pharmacy Compounding Advisory Committee voted to recommend adding six unregulated peptides—including the Wolverine stack—to the list of bulk-drug substances eligible for use in compounded medicines. The votes were nonbinding, however, and the FDA hasn't made a final decision.
The committee acted against the advice of the FDA's own scientists, who urged caution. Scientists cited scant human safety data, potential immune reactions, peptide impurities, and uncertainty over whether the peptides could harm people. Supporters countered that consumers are already buying peptides produced overseas and distributed through gray-market channels. Allowing some pharmacies to make compounds in the U.S. could provide a safer, more transparent alternative, they argued.
Anesthesiologist and pharmacist Anita Gupta, an adjunct professor at the Johns Hopkins University School of Medicine, says she sides with the FDA scientists. A renowned expert in health policy and pain management, Gupta served as an adviser on that same FDA committee from 2020 to 2025. During her tenure, the committee reviewed reports of contaminants and impurities found in unregulated peptides, along with evidence that peptides could provoke unwanted immune responses ranging from rashes to life-threatening allergic reactions.
"Companies and clinics selling peptides don't warn consumers about these very serious findings," she says. "For instance, rather than flagging peptides as immune modulators or invaders, they just talk about the positives."
The FDA committee's recommendation to let U.S. compounding pharmacies formulate the drugs isn't a solution, Gupta continues. Unlike FDA-approved drugs, those made by compounding pharmacies aren't evaluated by the FDA for safety and efficacy. And compounding itself has become a big business.
The compounding industry, once associated with independent pharmacies and hospital pharmacists tailoring medicines for patients with allergies and other specific needs, has evolved and is now valued at an estimated $6.8 billion, with some analysts predicting it will nearly double over the next decade.
Large telehealth companies are embracing the opportunity. The for-profit corporation Hims & Hers, for example, acquired compounding facilities in Ohio, Arizona, and California last year as part of a plan to expand into peptides for consumers increasingly interested in cognitive performance, preventive health, recovery science, and metabolic optimization, a company news release states.
For Gupta, scenarios like this suggest that the consumer demand for peptides is outpacing the science, she says. "It's also outpacing regulation and policy," she adds.
Potential versus proof
Neither Gupta nor Robinson dismisses the reasons people seek these drugs. Both physician-scientists treat patients living with chronic pain and know that conventional options can fall short. In her book Interventional Pain Medicine for Women's Health (Oxford University Press, 2026), Gupta advocates for a compassionate, patient-centered clinical approach for people who get little relief from nerve blocks, steroid injections, and prescription drugs.
"These treatments don't work for everyone, leading some to seek help from alternative medicine and wellness clinics, understandably so," she says.
Robinson agrees and says he believes patients have the right to make their own choices. But an informed decision takes knowing what the science tells them—and what it can't tell them, he adds.
That's difficult when someone notices improvement after an injection because, well, a torn tendon may start healing on its own, and a sore joint may feel better with rest. But another reason could explain the relief: the placebo effect.
"The placebo effect is real," Robinson says. "It can produce genuine physiological changes that make people feel better after taking something, even when the treatment hasn't been shown to be effective.
"But the only way to determine whether a peptide actually leads to improvement and works better than a placebo," he continues, "is to test it in well-designed clinical trials with a large enough group of people to distinguish a true treatment effect from an expectation, a coincidence, or the body's natural healing mechanisms."
The reasons people turn to peptides are easy to relate to and understand, considering that some injuries take months or years to heal, chronic pain can persist, and our bodies change as we age. A shot that can make us stronger, leaner, younger, and maybe more like Wolverine can be hard to resist.
Peptides might end up accomplishing some of what advocates claim. "We can only hope," Robinson says. But the drugs need what every effective modern medical treatment requires: rigorous testing in humans.
"There's real potential here," Robinson says. "But potential isn't the same as proof."
Risk Warning: Cryptocurrency is a unregulated virtual notoriously volatile instrument with a high level of risk. Any news, opinions, research, data, or other information contained within this website is provided for news reporting purposes as general market commentary and does not constitute investment or trading advice.
